Celgene Corp $139.84

down 0.00


15/4/2014 08:10 PM  |  NASDAQ : CELG  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get CELG Trend Analysis - it has underperformed the S&P 500 by 3%

Partner Headlines

  1. Short Interest Rises As Biotechs Fall (AMGN, CELG, DNDN)

    Benzinga
  2. Biotechs Struggling To Find A Bottom

    Benzinga
  3. Mid-Day Market Update: Apollo Drops After Q2 Results; MannKind Shares Spike ...

    Benzinga
  4. Mid-Morning Market Update: Markets Flat; Monsanto Earnings Beat Street ...

    Benzinga
  5. Morning Market Movers

    Benzinga
  6. Nasdaq Leads Another Up Day; S&P 500 Hits All-Time High

    IBD
  7. Gilead Sovaldi Scrips Falter As Biotechs Keep Falling

    IBD
  8. Market Wrap For March 27: Markets Lower Following Mixed Economic Data

    Benzinga
  9. Morgan Stanley's Top Biotech Pick is Biogen

    Benzinga
  10. Benzinga's Top Initiations

    Benzinga
  11. Celegene, Pharmacyclics Lead Biotech Short Interest Trend (CELG, MDVN, ...

    Benzinga
  12. Stocks On Pace To End Two-Session Slump

    IBD
  13. Stocks Notch Quiet Early Gains; Alexion, Celgene Top Nasdaq 100

    IBD
  14. Market Wrap For March 24: Markets On Two-Day Losing Streak?

    Benzinga
  15. Have We Seen The Top Of The Market?

    Benzinga
  16. Nasdaq Back Above Water; Green Plains Jumps

    IBD
  17. Dow, S&P 500 Up, Nasdaq Slips; Drugmakers Falling Hard

    IBD
  18. Market Wrap For March 19: Yellen Hints of Higher Rates & Sooner Than Expected ...

    Benzinga
  19. Celgene Reiterates Commitment to Improving Pancreatic Cancer Care in Europe

    Benzinga
  20. Keurig, Alaska Air Soar; Market Meanders

    IBD
  21. Stocks Open Mixed In Big Trade; Keurig, Amazon, Celgene Active

    IBD
  22. Stocks Open Higher, Turn Mixed After Employement Report

    IBD
  23. Biogen Idec Keeps Momentum Going With MS Drug Tecfidera

    IBD
  24. Here's Why The Buy Low, Sell High Strategy Is Risky

    IBD
  25. Top 4 Large-Cap Stocks In The Biotechnology Industry With The Lowest PEG ...

    Benzinga
  26. Market Wrap For February 13: Markets Close Higher; Nasdaq on a Six Day ...

    Benzinga
  27. You Can No Longer Ignore Biotech

    GuruFocus
  28. Why Accumulation Can Tip Odds For Quality Stocks

    IBD
  29. Alexion Takes Off On Outlook

    IBD
  30. Stocks Near Session Highs; Alexion, Under Armour Soar

    IBD
  31. Biogen's Report Sends Stock Up; Other Biotechs Follow

    IBD
  32. Stocks Fall; Facebook, Google Up After Hours

    IBD
  33. Facebook, Biogen, Sands Among Top Big Caps Reporting

    IBD
  34. Biotechs Still Hold Promise in 2014 and Beyond

    FoxBusiness
  35. There's A War Going On For Many Stocks At 50-Day Line

    IBD
  36. Pharmacyclics: Facts Behind $10B Market Cap

    YCharts
  37. Celgene to Report Q4 FY 2013 Results on January 30, 2014, Before the Market ...

    Benzinga
  38. Winners In 2013 Showed Fast Recent EPS Growth

    IBD
  39. Some of 2013's Best Performing Stocks Look Good for 2014

    Benzinga
  40. $10B Market By 2022: Pharmacyclic’s Piece Of It

    YCharts
  41. Top 2013 Drug Approvals: Pharma Stocks

    YCharts
  42. Biogen, Celgene Lead 5 Top Large-Cap Drugmakers

    IBD
  43. Celgene Results, Views Mixed

    IBD
  44. Facebook, Other Big Cap 20 Leaders Fall In Low Volume

    IBD
  45. Biotech Stocks Back On Top, Led By Biogen, Alexion

    IBD
  46. Stocks Fall In Higher Volume; Biogen, Celgene Drop

    IBD
  47. Stocks At Lows In Afternoon, But Jazz, LPL Hit Highs

    IBD
  48. Celgene Raises Long-Term Guidance, But Q4 Falls Short

    IBD
  49. Stocks Fall To New Session Lows; Chinese Stocks Gain

    IBD
  50. Celgene To Release Earnings At J.P. Morgan Event Mon.

    IBD
Trading Center